LipidBrick® is a novel range of proprietary cationic lipids dedicated to the formulation of LNPs for the development of mRNA-based vaccines and thera...
Meet our team at booth #33 during the 11th International mRNA Health Conference 2023 in Berlin, Germany on October 31st - 2nd November 2023. Don't miss the opportunity to check our poster presentation on: An innovative cationic lipid library for efficient and tunable mRNA-LNPs.
Poster : Novel generation of cationic LNP offer new possibilities in the delivery of RNA therapeutics
Lipid nanoparticles (LNPs) electric charge is known to control in vivo distribution and expression of mRNA-LNPs for intravascular (IV) administration. Whereas neutral LNPs predominantly end up targeting the liver,reducing the amount of cationic lipid in mRNA-LNPs creates a negative LNP, due to an excess of anionic mRNA, that targeted the spleen after IV injection, versus positively charged LNPs targeting the lung.A novel family of permanent cationic lipids has been developed to answer the next challenges in the development of RNA therapeutics. The combination of an imidazolium polar head and an accentuated molecularcone-shape through improved lipid tail branching, increases formulation stability and facilitates endosomal release, respectively. Due to these properties, cationic LNP (cLNP) have shown promising results in term ofstability, potency, in vivo distribution and targeting
Poster : An innovative cationic lipid library for efficient and tunable mRNA-LNPs
Lipid nanoparticles (LNP) have demonstrated high efficiency delivering RNA therapeutics in vivo. However, the properties of such nanoparticles obtained with conventional ionizable lipids are often hard to modulate,and especially their biodistribution profile. Such ionizable lipid-based nanoparticles often predominantly end up targeting the liver. One of the current challenges in the field consists of adjusting the particle chemical composition to the targeted application.
Here, we have characterized a library of 10 innovative imidazolium-based cationic lipids as key component of cationic LNPs (cLNP). We disclose their chemical structures and demonstrate their efficacy generating LNPs through characterization of their hydrodynamic diameters, Zeta potentials and encapsulation efficiencies. The resulting particles display high transfection efficiencies and have little to no impact on cell viability in vitro, on HEK-293 and CaCo-2 cell lines. In vivo, the biodistribution of the cLNP highly depends on the cationic lipid chemical structures, targeting mainly lungs and spleen. Among this library, we have identified one cationic lipid as a potent additive in Moderna‘s Spikevax formulation. We improve the transfection efficiency of this formulation by 20% in vitro in HEK293 and Caco-2 cell lines and modulate its biodistribution profile in vivo.
Discover Our Applications
Cell & Gene Therapy
Success of Gene and Cell Therapies is dependent on efficient production of viral vectors that require optimized transfection reagents and viral vector engineering
RNA/DNA in vivo delivery is the most powerful alternative to viral vectors for nucleic acid-based therapies. They offer substantial advantages in terms of reliability,safety and costs for nucleic-acid based therapies
Broad range of solutions is needed for manufacturing of functional proteins or antibodies at the desired scale in bacteria, yeast and mammalian cell expression systems
Optimised plasmid engineering and specific transfection reagents are key to enable protein expression in a wide range of adherent and suspension mammalian cell types